KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Common Equity (2016 - 2025)

Historic Common Equity for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $4.1 billion.

  • BeOne Medicines' Common Equity rose 2017.57% to $4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 2017.57%. This contributed to the annual value of $3.3 billion for FY2024, which is 579.83% down from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Common Equity is $4.1 billion, which was up 2017.57% from $3.8 billion recorded in Q2 2025.
  • BeOne Medicines' Common Equity's 5-year high stood at $6.1 billion during Q4 2021, with a 5-year trough of $3.3 billion in Q4 2024.
  • Moreover, its 5-year median value for Common Equity was $3.8 billion (2025), whereas its average is $4.1 billion.
  • In the last 5 years, BeOne Medicines' Common Equity skyrocketed by 5849.52% in 2021 and then crashed by 2852.33% in 2022.
  • BeOne Medicines' Common Equity (Quarter) stood at $6.1 billion in 2021, then dropped by 28.52% to $4.4 billion in 2022, then dropped by 19.3% to $3.5 billion in 2023, then decreased by 5.8% to $3.3 billion in 2024, then grew by 23.92% to $4.1 billion in 2025.
  • Its Common Equity stands at $4.1 billion for Q3 2025, versus $3.8 billion for Q2 2025 and $3.5 billion for Q1 2025.